Overview
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine brain tissue through controlled enzymatic proteolysis. It has been approved in over 40 countries (notably in Europe, Russia, China, and South Korea) for stroke recovery, traumatic brain injury, and dementia. It is one of the most clinically studied neurotrophic treatments, with over 200 clinical trials and 1,000+ publications.
Mechanism of action
Cerebrolysin mimics the action of endogenous neurotrophic factors (BDNF, GDNF, NGF, CNTF). Its peptide fragments cross the blood-brain barrier and activate multiple neuroprotective and neuroregenerative pathways: inhibiting calpain-mediated neuronal death, reducing amyloid-beta aggregation (relevant to Alzheimer's), promoting neurogenesis and synaptogenesis, modulating GSK-3β activity, and reducing neuroinflammation. It acts on the PI3K/Akt survival pathway and inhibits apoptosis.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| cognitive enhancement / neuroprotection | intramuscular | 5–10 mL | daily | Standard protocol: 5-10mL IM daily for 10-20 days. Stroke protocols use higher IV doses (30-50mL). Repeat courses every 3-6 months. |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
The CASTA trial (1,070 patients) showed improved neurological outcomes in acute ischemic stroke. Meta-analyses of Alzheimer's trials show consistent improvements in cognitive function (ADAS-cog scores). Studies in traumatic brain injury demonstrate faster recovery and better functional outcomes. A Cochrane review noted the evidence for stroke is 'promising but not conclusive' and called for more standardized trials. Used extensively in post-Soviet and Asian clinical practice with decades of real-world safety data. Not studied in large-scale Western trials.
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Cerebrolysin for synergistic effects.
Legal status
Approved as a prescription drug in 40+ countries. Not FDA-approved. Classified as a biological product. Available through international pharmacies.
Where to get it
Prescription required
Cerebrolysin is a prescription medication. Consult your healthcare provider or a licensed telehealth platform for access.